OCT 12, 2017 10:30 AM PDT

Hypersecretion of fibroblast-derived exosomes during chemotherapy promotes pancreatic cancer chemoresistance

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Archibald Assistant Professor of Cancer Biology, Department of Biological Sciences, Harper Cancer Research Institute, University of Notre Dame
    Biography
      I grew up in Cincinnati, Ohio where I found myself drawn to science even at a young age. I attended Florida A&M University and obtained a B.S. in Biology with a focus in Molecular Biology. During the summers I had opportunities to gain research experience through internships at USUHS, Pfizer, and the Genetics Institute. These experiences increased my desire to learn more about the mechanisms underlying disease progression.

      I continued my education at UNC-Chapel Hill by obtaining a PhD in Genetics and Molecular Biology in the lab of Terry Van Dyke, where I designed and created a new transgenic mouse model of prostate cancer that demonstrated the important role the microenvironment plays in tumor progression. As a Damon Runyon postdoctoral fellow with Dr. Hong Wu at UCLA, I chose to focus on pancreatic adenocarcinoma (PDAC), an under-researched disease with a high mortality rate, poor prognosis, and few therapeutic options. I developed mouse models to recapitulate the complexities of human PDAC in order to uncover new therapeutic strategies that could be translated to the human disease.

      My lab utilizes genetic models to address fundamental questions about how cell autonomous (e.g. genetic alteration) and cell non-autonomous (e.g. inflammation) mechanisms affect pancreatic cancer development. My focus is to uncover the central mechanisms through which the microenvironment aids tumor initiation, progression, and therapeutic resistance. A better understanding of these processes will not only help the development of more effective treatments for pancreatic cancer, but can be expanded to applications in a wide range of other diseases.

    Abstract:

    Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted membrane vesicles that range in size from 30–100 nm in diameter, released from epithelial cancer cells can promote drug resistance. However fibroblasts, not epithelial cells, make up the majority of the tumor bulk in PDAC. Despite the long-standing recognition of the prominence of the fibroblasts in PDAC, the mechanisms through which fibroblast-derived exosomes may contribute to chemoresistance following exposure to chemotherapy have not been studied. A molecular-level understanding of possible fibroblast-driven mechanisms of chemoresistance is essential for the development of more effective treatment strategies.

    Here, we show that CAFs exposed to chemotherapy play an active role in regulating the survival and proliferation of cancer cells through the hypersecretion of chemoresistance-promoting exosomes. We found that CAFs exposed to gemcitabine (GEM), the most widely used adjuvant therapy for PDAC, increase the release of exosomes. We utilized miRNA-SEQ analysis to identify miRs that were significantly increased in the exosomes of GEM-treated CAFs compared to treatment naïve CAFs and WT pancreatic fibroblasts. Five out of the top 10 hits were miRs that target PTEN. We utilized GW4869, a compound that inhibits exosome secretion, to functionally show in vitro and in vivo that blocking exosome release from GEM-treated CAFs reduces chemotherapy resistance in PDAC cells through restoration of PTEN expression. Collectively, these findings elucidate the role of CAF-derived exosomes in regulating PDAC chemoresistance and suggest that therapeutic strategies design to inhibit exosome release may lead to improved patient response.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources